Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Assessing Changes to the Gut Microbiota Following Radiation Therapy Against Bladder Cancer

EF 2022-23

Résumé
Bladder cancer is the 10th most common cancer worldwide, and 20% of those cases are muscle-invasive. The standard treatment is radical surgery, though, due to quality-of-life concerns, radiotherapy (RT) has emerged as an alternative. Despite this, 30% of patients do not respond to RT. A novel strategy to improve response is to add immune checkpoint inhibitors (ICIs), antibodies targeting various proteins to block tumour immunosuppression. A factor known to influence response to this combination is the gut microbiota, the bacteria residing in the gut, who also modulate host immunity. For a better efficacy of combination approaches, it is thus important to understand how RT affects the microbiota, as this in turn can alter its relationship with ICIs. The belief is that in a bladder cancer context, RT will induce changes to the microbiota. This study focuses on evaluating the impact of bladder radiation on the gut microbiota in an animal model. Additionally, we intend to assess the influence of radiation +/- ICI on the gut microbiota in a tumour model. In both aims, mice will be divided into several treatment groups (control, RT) and will be given RT and/or ICI on a specified schedule. To evaluate changes in the gut microbiota, stool samples will be collected over time and will be sent for DNA sequencing. The microbiome’s characteristics will then be analyzed using bioinformatics.?If previous trends hold true, RT will induce an immunosuppressive microbiota. It may thus be beneficial to wait before giving ICIs, until the microbiota returns to a more immunogenic state. Findings from this study can impact the efficacy of combination therapy leading to improved response and patient outcome.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486114
Name
Stendel Matthew C
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessing Changes to the Gut Microbiota Following Radiation Therapy Against Bladder Cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bladder Cancer; Immunotherapy; Microbiome; Pd-L1; Radiation
Abstract
Bladder cancer is the 10th most common cancer worldwide, and 20% of those cases are muscle-invasive. The standard treatment is radical surgery, though, due to quality-of-life concerns, radiotherapy (RT) has emerged as an alternative. Despite this, 30% of patients do not respond to RT. A novel strategy to improve response is to add immune checkpoint inhibitors (ICIs), antibodies targeting various proteins to block tumour immunosuppression. A factor known to influence response to this combination is the gut microbiota, the bacteria residing in the gut, who also modulate host immunity. For a better efficacy of combination approaches, it is thus important to understand how RT affects the microbiota, as this in turn can alter its relationship with ICIs. The belief is that in a bladder cancer context, RT will induce changes to the microbiota. This study focuses on evaluating the impact of bladder radiation on the gut microbiota in an animal model. Additionally, we intend to assess the influence of radiation +/- ICI on the gut microbiota in a tumour model. In both aims, mice will be divided into several treatment groups (control, RT) and will be given RT and/or ICI on a specified schedule. To evaluate changes in the gut microbiota, stool samples will be collected over time and will be sent for DNA sequencing. The microbiome’s characteristics will then be analyzed using bioinformatics.?If previous trends hold true, RT will induce an immunosuppressive microbiota. It may thus be beneficial to wait before giving ICIs, until the microbiota returns to a more immunogenic state. Findings from this study can impact the efficacy of combination therapy leading to improved response and patient outcome.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Stendel, Matthew C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~